2023 World Conference on Lung Cancer (Posters)-EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases

EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases - PDF(Slides)

Back to course

Pdf Summary

A retrospective study conducted by researchers from Sun Yat-sen University Cancer Center in China compared the effectiveness of immunotherapy plus chemotherapy (ICIchemo) versus bevacizumab plus chemotherapy (Bevachemo) as first-line treatment for non-small cell lung cancer (NSCLC) patients with brain metastases. The study aimed to determine the optimal treatment approach for NSCLC patients with brain metastases who do not have driver gene alterations.<br /><br />The study included 155 patients with advanced NSCLC and at least one measurable brain metastatic lesion who received either ICIchemo or Bevachemo as their first-line treatment. The primary endpoint of the study was intracranial progression-free survival (iPFS), with secondary endpoints including intracranial overall response rate (iORR), overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).<br /><br />The analysis of the patient characteristics showed no significant differences between the two treatment groups. However, the study found that ICIchemo was associated with a significantly improved iPFS compared to Bevachemo. Subgroup analysis showed that the benefits of ICIchemo were more pronounced in patients with PD-L1 positive expression. There were no significant differences in the systemic and intracranial objective response rates between the two groups.<br /><br />The study also evaluated adverse events associated with the treatments and found that both ICIchemo and Bevachemo were well-tolerated without any newly reported adverse events.<br /><br />In conclusion, the study suggests that ICIchemo is superior to Bevachemo as a first-line treatment for NSCLC patients with brain metastases. It significantly improved intracranial progression-free survival and overall survival, particularly in patients with PD-L1 positive expression. The study highlights the importance of immunotherapy in improving outcomes for NSCLC patients with brain metastases who do not have driver gene alterations.

Asset Subtitle

Li kun Chen

Meta Tag

Speaker Li kun Chen

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

immunotherapy plus chemotherapy

bevacizumab plus chemotherapy

first-line treatment

non-small cell lung cancer

NSCLC patients

brain metastases

driver gene alterations

intracranial progression-free survival

PD-L1 positive expression